Study reveals risk of skin cancer rises in patients with mastocytosis
Patients with systemic mastocytosis (SM) face significantly increased risks of melanoma and other skin cancers.
News
-
-
Case report examines SM as a cause of chronic diarrhea
A recently published case report highlighted systemic mastocytosis (SM) as a possible cause of chronic diarrhea.
-
Antisense therapy targeting KIT mutations shows potential as SM treatment
HT-KIT cut KIT protein levels by more than 80% and halted tumor growth in systemic mastocytosis (SM) models.
-
Researchers call for more individualized testing to diagnose systemic mastocytosis
Relying on BST levels to diagnose SM doesn’t account for individual variability influenced by genetic and physiological factors.
-
Current and future therapy options for systemic mastocytosis
Several newly approved and experimental treatments have shown promise in the management of systemic mastocytosis.
-
Case report: Diagnosis of indolent SM in the absence of classic symptoms
Indolent SM may be diagnosed despite the absence of classic symptoms associated with this disorder.
-
New insights into SM genetics could improve treatment and diagnosis
Different KIT mutations in patients with systemic mastocytosis (SM) appear to correlate with certain findings under the microscope.
-
Vitamin supplements may help relieve chronic itch, but more studies are needed
Vitamin supplements may help relieve chronic itch in people with conditions like systemic mastocytosis, especially when applied topically.
-
Case report: SM manifesting as back pain
The clinical manifestations of SM vary greatly from patient to patient, with some presenting back pain as an isolated symptom.
-
COVID-19 booster triggers severe immune response in man with SM
A patient with systemic mastocytosis suffered a life-threatening immune reaction after receiving an mRNA-1273 COVID-19 booster.
Learn more about SM
Sign up for the latest news, perspectives, and information about SM.
